Category: Neuromuscular Blockade

Revising Thoughts on Neuromuscular Blocking Reversal Agents

Deborah Wagner, Pharm.D., FASHP

Pharmacy and therapeutics (P&T) committees have the leadership necessary to create balance from the need and want perspective to what is fiscally reasonable. The case of neuromuscular blocker reversal agents fits these criteria uniquely.